# A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

> **NCT06577376** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Runshi Pharmaceutical Technology Co., Ltd** · enrollment: 252 (estimated)

## Conditions studied

- Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
- Expressing Human Epidermal Growth Factor Receptor-2 (HER-2)
- Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past

## Interventions

- **DRUG:** DP303c
- **DRUG:** Simmitinib tablets
- **DRUG:** Irinotecan liposomes
- **DRUG:** Paclitaxel or docetaxel or irinotecan

## Key facts

- **NCT ID:** NCT06577376
- **Lead sponsor:** Shanghai Runshi Pharmaceutical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-26
- **Primary completion:** 2026-08-26
- **Final completion:** 2027-08-26
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06577376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06577376, "A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06577376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*